Description
Cell-permeable. A potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase (IC₅₀ = 6 nM). Displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. TAK 165 inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
TAK-165 is a potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase (IC₅₀ = 6 nM). Displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. TAK 165 inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Alternate Name/Synonyms: (E)-4-((4-)1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-trifluoromethyl)oxazole; Mubritinib
Appearance: White to off-white solid
Formulation: N/A
CAS Number: 366017-09-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₅H₂₃F₃N₄O₂
Molecular Weight: 468.47
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (~25 mg/ml) or EtOH (~ 1.7 mg/ml)
Handling: Protect from light and air
Country of Origin: USA
Tag Line: A potent HER2 tyrosine kinase inhibitor
MDL Number: MFCD09954135
PubChem CID: 6444692
SMILES: C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)C=CC4=CC=C(C=C4)C(F)(F)F
InChi: InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
InChi Key: ZTFBIUXIQYRUNT-MDWZMJQESA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
48 months |